Awen M Gallimore

List of Publications by Year
in descending order

114 papers	8,173 citations	50276 46 h-index	48315 88 g-index
115 all docs	115 docs citations	115 times ranked	10793 citing authors

#	Article	IF	Citations
1	Exploiting ECM remodelling to promote immune-mediated tumour destruction. Current Opinion in Immunology, 2022, 74, 32-38.	5.5	8
2	Whole bloodâ€based measurement of SARSâ€CoVâ€2â€specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€organ cancers. Immunology, 2022, 165, 250-259.	4.4	21
3	Tumor-Associated High Endothelial Venules: Inroads Enabling Immune Control of Cancer Progression. Cancer Immunology Research, 2022, 10, 371-371.	3.4	0
4	Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances, 2022, 2, ltab025.	3.0	26
5	The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity. Trends in Cancer, 2021, 7, 214-225.	7.4	28
6	Molecular characterization of HLA class II binding to the LAGâ€3 T cell coâ€inhibitory receptor. European Journal of Immunology, 2021, 51, 331-341.	2.9	13
7	Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer, 2021, 124, 1552-1555.	6.4	2
8	Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. Immunology, 2021, 163, 389-398.	4.4	5
9	Sequential targeting of PI3KÎ´ and LAG3 as an effective anti-cancer approach. British Journal of Cancer, 2021, 125, 467-469.	6.4	7
10	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology, 2021, 2, .	2.8	7
11	T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology, 2021, 2, iqaa007.	2.8	19
12	Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. Cancer Immunology Research, 2020, 8, 1520-1531.	3.4	16
13	CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. Cell Reports, 2020, 32, 107885.	6.4	11
14	Enhanced antitumor immunity through sequential targeting of PI3KÎ´ and LAG3. , 2020, 8, e000693.		22
15	Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy, 2020, 69, 2063-2073.	4.2	9
16	The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology, 2019, 19, 98.	2.0	72
17	L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 1321.	4.8	50
18	Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry, 2019, 294, 20246-20258.	3.4	10

#	Article	IF	Citations
19	The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy, 2019, 68, 247-256.	4.2	10
20	Tâ€cell modulation by cyclophosphamide for tumour therapy. Immunology, 2018, 154, 62-68.	4.4	53
21	Mbd2 enables tumourigenesis within the intestine while preventing tumourâ€promoting inflammation. Journal of Pathology, 2018, 245, 270-282.	4.5	24
22	Hyperactive gp130/STAT3â€driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer, 2018, 143, 167-178.	5.1	43
23	Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation, 2018, 128, 1569-1580.	8.2	27
24	Defining High Endothelial Venules and Tertiary Lymphoid Structures in Cancer. Methods in Molecular Biology, 2018, 1845, 99-118.	0.9	23
25	Synergistic targeting of breast cancer stemâ€like cells by human Î³Î´ T cells and CD8⁺ T cells. Immunology and Cell Biology, 2017, 95, 620-629.	2.3	51
26	Treg Depletion Licenses T Cellâ€“Driven HEV Neogenesis and Promotes Tumor Destruction. Cancer Immunology Research, 2017, 5, 1005-1015.	3.4	78
27	Effect of Modified Vaccinia Ankaraâ€“5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, e172579.	7.1	51
28	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 6771-6780.	7.0	114
29	Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?. Frontiers in Immunology, 2017, 8, 1830.	4.8	168
30	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology, 2017, 35, 154-154.	1.6	1
31	A distinct chemokine axis does not account for enrichment of Foxp3⁺Â<scp>CD</scp>4⁺ T cells in carcinogenâ€induced fibrosarcomas. Immunology, 2015, 145, 94-104.	4.4	9
32	Oncogenic Properties of Apoptotic Tumor Cells in Aggressive B Cell Lymphoma. Current Biology, 2015, 25, 577-588.	3.9	96
33	High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology, 2015, 4, e974374.	4.6	60
34	Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	14
35	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunology, Immunotherapy, 2015, 64, 1271-1286.	4.2	161
36	CD200 Receptor Restriction of Myeloid Cell Responses Antagonizes Antiviral Immunity and Facilitates Cytomegalovirus Persistence within Mucosal Tissue. PLoS Pathogens, 2015, 11, e1004641.	4.7	16

#	Article	IF	Citations
37	Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods, 2015, 424, 131-135.	1.4	15
38	Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget, 2015, 6, 24649-24659.	1.8	16
39	Neutrophils Recruited by IL-22 in Peripheral Tissues Function as TRAIL-Dependent Antiviral Effectors against MCMV. Cell Host and Microbe, 2014, 15, 471-483.	11.0	58
40	Progression of carcinogenâ€induced fibrosarcomas is associated with the accumulation of naÃ¯ve CD4+ T cells via blood vessels and lymphatics. International Journal of Cancer, 2014, 134, 2156-2167.	5.1	7
41	The paradox of NKp46⁺natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon Î± treatment. Gut, 2014, 63, 515-524.	12.1	54
42	Interleukinâ€6 limits influenzaâ€induced inflammation and protects against fatal lung pathology. European Journal of Immunology, 2013, 43, 2613-2625.	2.9	143
43	Epithelial Barriers, Microbiota, and Colorectal Cancer. New England Journal of Medicine, 2013, 368, 282-284.	27.0	47
44	Flow cytometry makes all the difference. Journal of Hepatology, 2013, 59, 909-910.	3.7	0
45	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. Frontiers in Immunology, 2013, 4, 197.	4.8	70
46	Rapid innate control of antigen abrogates adaptive immunity. Immunology, 2013, 138, 293-297.	4.4	2
47	High endothelial venules. OncoImmunology, 2013, 2, e24272.	4.6	4
48	Escalating Regulation of 5T4-Specific IFN-Î³+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy. Cancer Immunology Research, 2013, 1, 416-425.	3.4	15
49	T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion. Cancer Research, 2012, 72, 5473-5482.	0.9	97
50	Hunting for clues. OncoImmunology, 2012, 1, 1163-1164.	4.6	0
51	Suppression of tumour-specific CD4⁺T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut, 2012, 61, 1163-1171.	12.1	127
52	Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications, 2012, 3, 665.	12.8	36
53	The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺and CD8⁺Tâ€cell immunity. FASEB Journal, 2012, 26, 3575-3586.	0.5	48
54	Avidity of influenzaâ€specific memory <scp>CD</scp>8⁺<scp>T</scp>â€cell populations decays over time compromising antiviral immunity. European Journal of Immunology, 2012, 42, 3235-3242.	2.9	3

#	Article	IF	Citations
55	T cell subsets and colorectal cancer: Discerning the good from the bad. Cellular Immunology, 2012, 279, 21-24.	3.0	17
56	Rapid early innate control of hepatitis C virus during IFN â€Î± treatment compromises adaptive CD 4 + T â€cell immunity. European Journal of Immunology, 2012, 42, 2383-2394.	2.9	15
57	Complementâ€induced protection: an explanation for the limitations of cellâ€based tumour immunotherapies. Immunology and Cell Biology, 2012, 90, 869-871.	2.3	3
58	Setting the threshold for extraâ€thymic differentiation of Foxp3⁺ Tregs: TGFâ€Î²â€dependent and Tâ€cell autonomous. European Journal of Immunology, 2011, 41, 1218-1220.	2.9	0
59	Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptideâ€“MHCI Tetramer Staining. Journal of Immunology, 2011, 187, 654-663.	0.8	34
60	Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax, 2011, 66, 368-374.	5.6	39
61	Delineating Immune-Mediated Mechanisms Underlying Hair Follicle Destruction in the Mouse Mutant Defolliculated. Journal of Investigative Dermatology, 2011, 131, 572-579.	0.7	31
62	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors. Cancer Research, 2011, 71, 736-746.	0.9	112
63	Antigen Specificity Determines the Pro- or Antitumoral Nature of CD8+ T Cells. Journal of Immunology, 2010, 184, 607-614.	0.8	12
64	Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology, 2010, 131, 583-592.	4.4	47
65	Type I Interferon (IFNÎ±) Acts Directly on Human Memory CD4+T Cells Altering Their Response to Antigen. Journal of Immunology, 2009, 183, 2915-2920.	0.8	38
66	CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?. Journal of Immunology, 2009, 182, 5203-5207.	0.8	46
67	Regulatory T cells and tumour immunity â€“ observations in mice and men. Immunology, 2008, 123, 157-163.	4.4	94
68	CD62L (L-Selectin) Down-Regulation Does Not Affect Memory T Cell Distribution but Failure to Shed Compromises Anti-Viral Immunity. Journal of Immunology, 2008, 180, 198-206.	0.8	38
69	Interleukin-6 Is Crucial for Recall of Influenza-Specific Memory CD4+ T Cells. PLoS Pathogens, 2008, 4, e1000006.	4.7	89
70	Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFNÎ³-dependent iNOS expression in the vasculature of healthy mice. Blood, 2008, 111, 5187-5194.	1.4	43
71	The Influence of CD25+ Cells on the Generation of Immunity to Tumour Cell Lines in Mice. Novartis Foundation Symposium, 2008, , 149-157.	1.1	11
72	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. European Journal of Immunology, 2007, 37, 758-767.	2.9	25

#	Article	IF	Citations
73	Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology, 2007, 37, 798-806.	2.9	30
74	CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. European Journal of Immunology, 2007, 37, 1266-1274.	2.9	31
75	Holding T cells in check â€“ a new role for complement regulators?. Trends in Immunology, 2006, 27, 102-108.	6.8	100
76	CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer. PLoS ONE, 2006, 1, e129.	2.5	183
77	Regulating the immune response to tumours. Advanced Drug Delivery Reviews, 2006, 58, 948-961.	13.7	51
78	T-Cell Costimulation. New England Journal of Medicine, 2006, 355, 2594-2595.	27.0	8
79	Role of Immunoproteasomes in Cross-Presentation. Journal of Immunology, 2006, 177, 983-990.	0.8	74
80	Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands. Microbes and Infection, 2005, 7, 729-737.	1.9	3
81	Complement: central to innate immunity and bridging to adaptive responses. Immunology Letters, 2005, 97, 171-179.	2.5	178
82	Cutting Edge: Murine CD59a Modulates Antiviral CD4+ T Cell Activity in a Complement-Independent Manner. Journal of Immunology, 2005, 175, 7098-7102.	0.8	67
83	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273.	0.8	89
84	TCR affinity and negative regulation limit autoimmunity. Nature Medicine, 2004, 10, 1234-1239.	30.7	138
85	CD25+ regulatory T cells and tumor immunity. Immunology Letters, 2003, 85, 141-143.	2.5	29
86	The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology, 2003, 109, 68-75.	4.4	24
87	Immunodominance of an Antiviral Cytotoxic T Cell Response Is Shaped by the Kinetics of Viral Protein Expression. Journal of Immunology, 2003, 171, 5415-5422.	0.8	96
88	Exogenous Peptides Delivered by Ricin Require Processing by Signal Peptidase for Transporter Associated with Antigen Processing-Independent MHC Class I-Restricted Presentation. Journal of Immunology, 2002, 169, 99-107.	0.8	23
89	Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nature Medicine, 2002, 8, 373-378.	30.7	276
90	Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell, 2002, 2, 315-322.	16.8	29

#	Article	IF	Citations
91	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. European Journal of Immunology, 2002, 32, 3267-3275.	2.9	257
92	Regulation of tumour immunity by CD25+ T cells. Immunology, 2002, 107, 5-9.	4.4	77
93	Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. , 2002, 32, 3267.		8
94	Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity, 2002, 2, 1.	3.2	125
95	Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. European Journal of Immunology, 2001, 31, 450-458.	2.9	56
96	Deletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment. Nature Immunology, 2001, 2, 1167-1173.	14.5	70
97	Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. European Journal of Immunology, 2001, 31, 450-458.	2.9	1
98	Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. European Journal of Immunology, 2000, 30, 1823-1829.	2.9	82
99	MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. European Journal of Immunology, 2000, 30, 3623-3633.	2.9	148
100	Inducible Costimulator Protein (Icos) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection. Journal of Experimental Medicine, 2000, 192, 53-62.	8.5	192
101	Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine, 2000, 19, 764-778.	3.8	329
102	Developmental Regulation of Lck Targeting to the CD8 Coreceptor Controls Signaling in Naive and Memory T Cells. Journal of Experimental Medicine, 1999, 189, 1521-1530.	8.5	138
103	Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1999, 29, 2213-2222.	2.9	27
104	OX40-Deficient Mice Are Defective in Th Cell Proliferation but Are Competent in Generating B Cell and CTL Responses after Virus Infection. Immunity, 1999, 11, 699-708.	14.3	297
105	Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews, 1998, 164, 29-32.	6.0	67
106	A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology, 1998, 28, 3301-3311.	2.9	54
107	The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leaderâ€"derived T cell epitope. Molecular Immunology, 1998, 35, 581-591.	2.2	17
108	Induction and Exhaustion of Lymphocytic Choriomeningitis Virusâ€"specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class Iâ€"Peptide Complexes. Journal of Experimental Medicine, 1998, 187, 1383-1393.	8.5	688

#	Article	IF	Citations
109	Protective Immunity Does Not Correlate with the Hierarchy of â€‰Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides. Journal of Experimental Medicine, 1998, 187, 1647-b-1657.	8.5	252
110	Cytotoxic T cellsâ€”protection from disease progressionâ€”protection from infection. Immunology Letters, 1996, 51, 125-128.	2.5	27
111	The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics, 1995, 41, 59-68.	2.4	86
112	HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Medicine, 1995, 1, 59-64.	30.7	771
113	Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine, 1995, 1, 1167-1173.	30.7	200
114	Cytotoxic T lymphocyte epitopes shared between HIVâ€1, HIVâ€2, and SIV. Journal of Medical Primatology, 1993, 22, 119-123.	0.6	12